392 related articles for article (PubMed ID: 18025191)
1. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.
Lucas JA; Menke J; Rabacal WA; Schoen FJ; Sharpe AH; Kelley VR
J Immunol; 2008 Aug; 181(4):2513-21. PubMed ID: 18684942
[TBL] [Abstract][Full Text] [Related]
3. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
[TBL] [Abstract][Full Text] [Related]
4. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
Zhu B; Guleria I; Khosroshahi A; Chitnis T; Imitola J; Azuma M; Yagita H; Sayegh MH; Khoury SJ
J Immunol; 2006 Mar; 176(6):3480-9. PubMed ID: 16517716
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
6. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
7. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
8. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
9. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival.
Shen L; Jin Y; Freeman GJ; Sharpe AH; Dana MR
J Immunol; 2007 Sep; 179(6):3672-9. PubMed ID: 17785803
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.
Cao J; Liu FX; Yu MX
Chin Med J (Engl); 2009 Aug; 122(16):1941-6. PubMed ID: 19781375
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
Ishida M; Iwai Y; Tanaka Y; Okazaki T; Freeman GJ; Minato N; Honjo T
Immunol Lett; 2002 Oct; 84(1):57-62. PubMed ID: 12161284
[TBL] [Abstract][Full Text] [Related]
13. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.
Bu DX; Tarrio M; Maganto-Garcia E; Stavrakis G; Tajima G; Lederer J; Jarolim P; Freeman GJ; Sharpe AH; Lichtman AH
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1100-7. PubMed ID: 21393583
[TBL] [Abstract][Full Text] [Related]
14. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.
Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC
Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994
[TBL] [Abstract][Full Text] [Related]
15. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.
Haspot F; Fehr T; Gibbons C; Zhao G; Hogan T; Honjo T; Freeman GJ; Sykes M
Blood; 2008 Sep; 112(5):2149-55. PubMed ID: 18577709
[TBL] [Abstract][Full Text] [Related]
16. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
[TBL] [Abstract][Full Text] [Related]
17. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2.
Huber S; Hoffmann R; Muskens F; Voehringer D
Blood; 2010 Oct; 116(17):3311-20. PubMed ID: 20625006
[TBL] [Abstract][Full Text] [Related]
18. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice.
Kinoshita K; Tesch G; Schwarting A; Maron R; Sharpe AH; Kelley VR
J Immunol; 2000 Jun; 164(11):6046-56. PubMed ID: 10820290
[TBL] [Abstract][Full Text] [Related]
19. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
20. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand.
Hirata S; Senju S; Matsuyoshi H; Fukuma D; Uemura Y; Nishimura Y
J Immunol; 2005 Feb; 174(4):1888-97. PubMed ID: 15699115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
